Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Reksa Dana Danareksa ETF Indonesia Top 40 (XDIF) Price & Performance

Brigit Biofarmaka Teknologi Tbk.Trade
Reksa Dana Danareksa ETF Indonesia Top 40Trade

Price performance (Past 24H)

Key statistics

Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Danareksa ETF Indonesia Top 40 — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp254 (market cap 172.82B, 592.2K 24h volume), while Reksa Dana Danareksa ETF Indonesia Top 40 trades at Rp422 (market cap 29.39B, 300 24h volume). The key difference: Brigit Biofarmaka Teknologi Tbk. is far larger — about 5.9× Reksa Dana Danareksa ETF Indonesia Top 40's market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (592.2K versus 300). Which is the better fit depends on your goals.

OBATXDIF
Market Cap
172.82B29.39B
Volume
592.2K300
Lot
5.92K3
Turnover
147.05M126.7K
Average Price
248.31422.33
Value
147.05M126.7K
Indicative Equilibrium Price
254
Indicative Equilibrium Volume
10

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

OBAT
View details

About Brigit Biofarmaka Teknologi Tbk.

PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.

Read more on OBAT

About Reksa Dana Danareksa ETF Indonesia Top 40

Read more on XDIF